Is COMPASS Pathways (CMPS) Undervalued As Phase 3 Progress And FDA Review Advance?

COMPASS Pathways (NasdaqGS:CMPS) is back in focus after reporting 26 week Phase 3 COMP006 data for its COMP360 psilocybin candidate in treatment resistant depression, alongside supportive regulatory progress and new PTSD analysis.

See our latest analysis for COMPASS Pathways.

Despite the latest positive trial readout, COMPASS Pathways' share price has been volatile, with a 1 day share price return that declined 6.61% and a 7 day share price return that declined 8.60%. However, the 90 day share price return of 86.64% and 1 year total shareholder return of 220.36% point to strong momentum building over a longer period.

If this kind of clinical news has your attention, it could be a good moment to broaden your watchlist with other healthcare focused AI opportunities using the 39 healthcare AI stocks.

Bulls see COMPASS Pathways as a late stage psychedelic leader with supportive data and regulators, while bears focus on losses and execution risk. Given the recent share price swing, which case does the current valuation lean toward?

Most Popular Narrative: 49.2% Undervalued

COMPASS Pathways' most followed valuation narrative places fair value at $24.47, well above the last close of $12.43. This sets up a sharply discounted story.

Constructive interactions with both the FDA and the VA on future PTSD development, alongside finalization of a late stage PTSD protocol and selection of a CRO, expand COMP360 into a second large mental health indication. This could diversify and increase the long term revenue base and support earnings durability.

Read the complete narrative.

Curious what kind of revenue ramp, margins and future earnings multiple are reflected in that fair value gap? The full narrative spells out a bold financial roadmap.

Result: Fair Value of $24.47 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, COMPASS Pathways' story can break if Phase 3 outcomes, approvals or PTSD expansion timing slip, or if higher spending forces fresh equity raises that dilute shareholders.

Find out about the key risks to this COMPASS Pathways narrative.

Next Steps

If the mixed bullish and cautious views on COMPASS Pathways have you thinking, now is the time to review the facts yourself and move quickly. You can start with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond COMPASS Pathways?

Do not stop at COMPASS Pathways. Broaden your opportunity set with a few focused stock lists that can quickly surface ideas aligned with how you like to invest.

• Target potential mispricing by scanning companies that currently screen as attractively valued using the 49 high quality undervalued stocks.
• Build more resilience into your portfolio by focusing on companies with stronger finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for overlooked opportunities before the crowd pays attention by reviewing the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com